AVROBIO - Model AVR-RD-01 -Gene Therapy for Fabry Disease

AVROBIO’s investigational gene therapy for Fabry disease is currently being studied in two clinical trials. An investigator-sponsored Phase 1 trial in Canada is fully enrolled, with five patients dosed. Nine treatment-naïve patients have been dosed in the FAB-GT Phase 2 trial, which continues to enroll in Australia, the U.S. and Canada.